FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma December 21, 2017October 19, 2019 by / Share This.....LinkedinTwitterFacebookGoogleEmailDownload PDF Related News: FDA grants Breakthrough Therapy Designation for…[Ad hoc announcement pursuant to Art. 53 LR] Roche’s…Roche's Elecsys Amyloid Plasma Panel granted…Thermo Fisher Scientific Opens Cell Therapy Facility…Rakuten Medical and Shimadzu Enroll First Patient in…FDA accepts supplemental Biologics License…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)